18F-flourodeoxy-glucose PET/computed tomography in brain tumors: Value to patient management and survival outcomes

Rick Wray; Lilja Solnes; Esther Mena; Avner Meoded; Rathan M. Subramaniam

doi:10.1016/j.cpet.2015.03.011

¹⁸F-flourodeoxy-glucose PET/computed tomography in brain tumors: Value to patient management and survival outcomes

Rick Wray, Lilja Solnes, Esther Mena, Avner Meoded, Rathan M. Subramaniam

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

¹⁸F-flourodeoxy-glucose (FDG) PET/computed tomography (CT) is most useful in the evaluation of primary central nervous system (CNS) lymphoma, important in diagnosis, pretherapy prognosis, and therapy response evaluation. Utility in working up gliomas is less effective, and FDG PET/CT is most helpful when MR imaging is unclear. FDG avidity correlates with the grade of gliomas. FDG PET/CT can be used to noninvasively identify malignant transformation. Establishing this change in the disease process has significant effects on patient management and survival outcome.

Original language	English (US)
Pages (from-to)	423-430
Number of pages	8
Journal	PET Clinics
Volume	10
Issue number	3
DOIs	https://doi.org/10.1016/j.cpet.2015.03.011
State	Published - Jul 1 2015

Keywords

Brain
Cancer
Central nervous system neoplasm
PET
PET/computed tomography
Patient management
Survival outcomes
Tumor

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2015.03.011

Cite this

@article{8c76d31f95444babb01a51d0ab9dd400,

title = "18F-flourodeoxy-glucose PET/computed tomography in brain tumors: Value to patient management and survival outcomes",

abstract = "18F-flourodeoxy-glucose (FDG) PET/computed tomography (CT) is most useful in the evaluation of primary central nervous system (CNS) lymphoma, important in diagnosis, pretherapy prognosis, and therapy response evaluation. Utility in working up gliomas is less effective, and FDG PET/CT is most helpful when MR imaging is unclear. FDG avidity correlates with the grade of gliomas. FDG PET/CT can be used to noninvasively identify malignant transformation. Establishing this change in the disease process has significant effects on patient management and survival outcome.",

keywords = "Brain, Cancer, Central nervous system neoplasm, PET, PET/computed tomography, Patient management, Survival outcomes, Tumor",

author = "Rick Wray and Lilja Solnes and Esther Mena and Avner Meoded and Subramaniam, {Rathan M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.cpet.2015.03.011",

language = "English (US)",

volume = "10",

pages = "423--430",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - 18F-flourodeoxy-glucose PET/computed tomography in brain tumors

T2 - Value to patient management and survival outcomes

AU - Wray, Rick

AU - Solnes, Lilja

AU - Mena, Esther

AU - Meoded, Avner

AU - Subramaniam, Rathan M.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - 18F-flourodeoxy-glucose (FDG) PET/computed tomography (CT) is most useful in the evaluation of primary central nervous system (CNS) lymphoma, important in diagnosis, pretherapy prognosis, and therapy response evaluation. Utility in working up gliomas is less effective, and FDG PET/CT is most helpful when MR imaging is unclear. FDG avidity correlates with the grade of gliomas. FDG PET/CT can be used to noninvasively identify malignant transformation. Establishing this change in the disease process has significant effects on patient management and survival outcome.

AB - 18F-flourodeoxy-glucose (FDG) PET/computed tomography (CT) is most useful in the evaluation of primary central nervous system (CNS) lymphoma, important in diagnosis, pretherapy prognosis, and therapy response evaluation. Utility in working up gliomas is less effective, and FDG PET/CT is most helpful when MR imaging is unclear. FDG avidity correlates with the grade of gliomas. FDG PET/CT can be used to noninvasively identify malignant transformation. Establishing this change in the disease process has significant effects on patient management and survival outcome.

KW - Brain

KW - Cancer

KW - Central nervous system neoplasm

KW - PET

KW - PET/computed tomography

KW - Patient management

KW - Survival outcomes

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84931828650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931828650&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2015.03.011

DO - 10.1016/j.cpet.2015.03.011

M3 - Review article

C2 - 26099676

AN - SCOPUS:84931828650

SN - 1556-8598

VL - 10

SP - 423

EP - 430

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -